Search
All Clinical Trials
A listing of 23094 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
3853 - 3864 of 23094
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Mucopolysaccharidosis VII Disease Monitoring Program
Recruiting
The objectives of this study are to characterize MPS VII disease presentation and progression and assess long-term effectiveness and safety, including hypersensitivity reactions and immunogenicity of vestronidase alfa.
Gender:
ALL
Ages:
All
Trial Updated:
05/22/2025
Locations: Children's Hospital of Orange County, Orange, California +13 locations
Conditions: Mucopolysaccharidosis VII, MPS VII, MPS 7, Sly Syndrome
NOLA (NeuWave Observational Liver Ablation) Registry
Recruiting
This is a multicenter, observational registry that follows patients for a total of 5 years from the date of the first liver ablation procedure with the NEUWAVE Microwave Ablation System.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
05/22/2025
Locations: Loma Linda University Medical Center, Loma Linda, California +29 locations
Conditions: Cancer of the Liver, Liver Cancer, Neoplasms, Liver
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/22/2025
Locations: Central Research Associates, Birmingham, Alabama +150 locations
Conditions: Migraine
GDNF Gene Therapy for Multiple System Atrophy
Recruiting
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.
Gender:
ALL
Ages:
Between 35 years and 75 years
Trial Updated:
05/22/2025
Locations: University of California Irvine, Irvine, California +6 locations
Conditions: Multiple System Atrophy
Post-Market Clinical Follow-Up onTVT EXACT® Continence System
Recruiting
The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).
Gender:
FEMALE
Ages:
21 years and above
Trial Updated:
05/22/2025
Locations: Duke University, Durham, North Carolina +7 locations
Conditions: Stress Urinary Incontinence
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Recruiting
This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.
Gender:
ALL
Ages:
Between 6 years and 45 years
Trial Updated:
05/22/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas +13 locations
Conditions: Congenital Myotonic Dystrophy
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Recruiting
This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study.
This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated do... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/22/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +8 locations
Conditions: Acute Myeloid Leukemia
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Recruiting
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and preliminary clinical activity at the RP2D. Part 4 (RP2D expansion) will assess the overall complete response (CR) in participants with intermediate-risk-non-muscle invasive bladder cancer (IR-NMIBC; means the cancer cells are only in the bladder's inner lining).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Southern California, Los Angeles, California +40 locations
Conditions: Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
Recruiting
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (dose selection) and further to evaluate safety and tolerability of bleximenib in combination with AML directed therapies at the RP2D(s) (dose expansion).
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/22/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +31 locations
Conditions: Leukemia, Myeloid, Acute
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Recruiting
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
05/22/2025
Locations: Massachusetts General Hospital ., Boston, Massachusetts +16 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Recruiting
The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe hepatic impairment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: The Oncology Institute of Hope & Innovation - Lynwood, Lynwood, California +13 locations
Conditions: Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma
Cochlear Implants in Young Children With SSD
Recruiting
The goal of this clinical trial is to investigate the safety and effectiveness of cochlear implantation in infants and toddlers with single-sided deafness.
The main questions it aims to answer are:
* Are cochlear implants an effective treatment of single-sided deafness in infants and toddlers?
* Are cochlear implants a safe treatment for single-sided deafness in infants and toddlers?
Participants will receive a cochlear implant and be followed until they are five years old. During those five... Read More
Gender:
ALL
Ages:
Between 7 months and 71 months
Trial Updated:
05/22/2025
Locations: The Children's Cochlear Implant Center at UNC, Durham, North Carolina
Conditions: Single Sided Deafness, Unilateral Deafness, Hearing Loss, Unilateral, Hearing Loss, Congenital Hearing Loss, Deafness One Ear
3853 - 3864 of 23094